ChiCTR-IIR-17013331
正在进行
/
/
/
2017-11-10
/
/
Allergic Rhinitis
Clinical Efficacy and Safety of Oral Supplement of Allium ascalonicum L. in Patients with Allergic Rhinitis
Clinical Efficacy and Safety of Oral Supplement of Allium ascalonicum L. in Patients with Allergic Rhinitis
(1) To determine the efficacy and safety of oral supplement of Allium ascalonicum L. in patients with mild-persistent allergic rhinitis (2) To compare the efficacy and safety of oral supplement of Allium ascalonicum L. to placebo in patients with mild-persistent allergic rhinitis (3) To observe the possible adverse effects of oral supplement of Allium ascalonicum L.
随机平行对照
Ⅱ期
Randomization will be performed according to computer-generated schedule as described in www.Randomization.com
/
Chiang Mai University
/
60
/
2017-11-15
2018-11-15
/
Subjects will be male and female, aged 18-60 years old who were diagnosed with mild-persistent allergic rhinitis (according to ARIA 2008 guidelines) with previous history of positive skin prick test or presence of positive skin prick test to at-least 1 allergen during screening period. They must have total nasal symptom scores (TNSS) ≥ 6 within prior 2 weeks and the score of nasal congestion must not exceed 2 (≤ 2). All subjects must be explained and clearly understand the details of this research protocol, and give their written informed consent before entering the study.；
请登录查看Subjects were excluded from the study if they had: (1) marked anatomical abnormality of nose such as nasal septum deviation, nasal polyposis, unilateral obstruction; (2) infection of respiratory tract within 2 weeks before the study; (3) use of oral or intranasal corticosteroids within 4 weeks before the study; (4) nasal surgery within 4 weeks before the study; (5) currently on immunotherapy or previously received immunotherapy within 1 year before entering the study; (6) hypersensitivity of cetirizine or ingredient of the drug; (7) hypersensitivity of Allium ascalonicum L. or chemical in Allium ascalonicum L.; (8) history of asthma, cancer, hepatic diseases (AST, ALT > 1.5 times of the upper limit of normal range) or renal disease (eGFR < 50 ml/min), heart disease (using the digoxin); (9) pregnancy or breastfeeding.；
请登录查看Faculty of Medicine, Chiang Mai University
/
汉氏联合2026-06-09
求实药社2026-06-09
肝脏时间2026-06-09
求实药社2026-06-09
求实药社2026-06-09
上海儿童医学中心2026-06-09
动脉网-最新2026-06-09
数字医疗2026-06-09
干细胞与外泌体2026-06-09
干细胞与外泌体2026-06-09
400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
川公网安备51019002008863号
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
“坚决打赢禁毒人民战争”专栏 法律法规 | 美、墨、欧盟管制品种
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网 医药招商网
